Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | FAAH | O00519 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.54 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454821 | 1.00 | HTR2A (0.66) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL2243718 | 0.89 | HTR2A (0.65) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL2241359 | 0.89 | HTR2A (0.57) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL2244547 | 0.88 | HTR2A (0.56) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL2242091 | 0.88 | HTR2A (0.60) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL4652726 | 0.87 | MAPT (0.62) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL2243980 | 0.87 | KMT2A (0.62) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL2243480 | 0.87 | CDK2 (0.73) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL2246486 | 0.87 | HTR2A (0.62) | HTR2AKMT2AMEN1FAAHMAPT | |
| SCHEMBL11956684 | 0.87 | KMT2A (0.62) | HTR2AKMT2AMEN1FAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275096-A2 | Neurogenesis via modulation of the muscarinic receptors | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| EP-2275095-A2 | Neurogenesis by muscarinic receptor modulation | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| EP-2258359-A2 | Neurogenesis by muscarinic receptor modulation with sabcomelin | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| EP-2258357-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| US-4880826-A | Melatonin antagonist | ZISAPEL NAVA (IL) | 1989-11-14 | — | — | US | claimed |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| US-11918557-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230210810-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2023-07-06 | — | — | US | disclosed |
| US-20210161854-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2021-06-03 | — | — | US | disclosed |
| US-10945988-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3620794-A1 | DETERMINING A CIRCADIAN RHYTHM | Vanda Pharmaceuticals Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10555919-B2 | Melatonin in autoimmune disease | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050020664-A1 | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-01-27 | — | — | US | disclosed |
| EP-1331935-A4 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMA 1991 (IL) | 2004-12-01 | — | — | EP | disclosed |
| US-6780884-B2 | NOVEL COMPOUNDS RELATED TO MELATONIN, BUT WITH PHARMACOLOGICAL OR PHARMACOKINETIC PROFILES DIFFERENT FROM MELATONIN | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-08-24 | — | — | US | disclosed |
| US-20040029950-A1 | Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-02-12 | — | — | US | disclosed |
| EP-1331935-A2 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002028347-A2 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2002-04-11 | — | — | WO | disclosed |
| US-4880826-A | Melatonin antagonist | ZISAPEL NAVA (IL) | 1989-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020664-A1 | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | TPH1, TPH2, TPSB2 | HTR2A 8/4885KMT2A 619/4885MEN1 50/4885 |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | HTR2A 39/4885KMT2A 856/4885MEN1 1576/4885 |
| US-20230210810-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | HTR2A 39/4885KMT2A 856/4885MEN1 1576/4885 |
| US-20040029950-A1 | Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them | TPH2, TPH1, TPSD1 | HTR2A 14/4885KMT2A 300/4885MEN1 306/4885 |
| US-10945988-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | HTR2A 39/4885KMT2A 856/4885MEN1 1576/4885 |
| US-20210161854-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | HTR2A 39/4885KMT2A 856/4885MEN1 1576/4885 |
| US-11918557-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | HTR2A 39/4885KMT2A 856/4885MEN1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.